Rodgers Brothers Inc. Raises Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Rodgers Brothers Inc. lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 68,714 shares of the company’s stock after purchasing an additional 600 shares during the quarter. Johnson & Johnson accounts for about 2.3% of Rodgers Brothers Inc.’s portfolio, making the stock its 6th biggest position. Rodgers Brothers Inc.’s holdings in Johnson & Johnson were worth $11,293,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. raised its position in shares of Johnson & Johnson by 0.7% during the first quarter. BlackRock Inc. now owns 189,690,998 shares of the company’s stock worth $31,175,717,000 after purchasing an additional 1,379,656 shares during the period. Geode Capital Management LLC raised its position in shares of Johnson & Johnson by 1.8% during the first quarter. Geode Capital Management LLC now owns 40,825,241 shares of the company’s stock worth $6,691,186,000 after purchasing an additional 716,136 shares during the period. Norges Bank acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $4,370,566,000. Morgan Stanley raised its position in Johnson & Johnson by 0.8% in the 1st quarter. Morgan Stanley now owns 24,305,948 shares of the company’s stock valued at $3,994,681,000 after buying an additional 194,920 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Johnson & Johnson by 4.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 17,236,904 shares of the company’s stock valued at $2,712,680,000 after buying an additional 692,267 shares during the last quarter. 66.60% of the stock is currently owned by institutional investors.

Shares of NYSE:JNJ traded up $0.96 during trading on Thursday, hitting $170.45. 237,056 shares of the company were exchanged, compared to its average volume of 6,223,537. The stock has a market capitalization of $448.86 billion, a PE ratio of 30.07, a price-to-earnings-growth ratio of 2.71 and a beta of 0.71. Johnson & Johnson has a fifty-two week low of $133.65 and a fifty-two week high of $173.65. The firm has a fifty day simple moving average of $167.25. The company has a current ratio of 1.28, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 20th. The company reported $2.48 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.29 by $0.19. The firm had revenue of $23.31 billion for the quarter, compared to analyst estimates of $22.54 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 17.95%. The business’s quarterly revenue was up 27.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.67 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 9.51 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 7th. Shareholders of record on Tuesday, August 24th will be given a dividend of $1.06 per share. This represents a $4.24 annualized dividend and a dividend yield of 2.49%. The ex-dividend date of this dividend is Monday, August 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is 52.80%.

A number of brokerages recently issued reports on JNJ. Morgan Stanley began coverage on Johnson & Johnson in a research report on Friday, May 28th. They issued an “overweight” rating and a $187.00 target price on the stock. Credit Suisse Group set a $193.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research report on Monday, June 7th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $190.38.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Article: What is Forex?

Want to see what other hedge funds are holding JNJ? Visit to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.